Brief: 10X Genomics Q4 Revenue Growth 18%
15/02/2024 21:05
Feb 15 (Reuters) - 10X Genomics Q4 gross margin 63%. * Q4 net income USD -49 million vs. IBES estimate USD -42.2 million * Q4 operating income USD -55.2 million vs. IBES estimate USD -43 million * outlook FY revenue USD 670-690 million
Recent news on 10x Genomics
See all newsBrief: 10X Genomics Announces New Collaboration To Advance Single Cell And Spatial Applications Across Solid Tumors And Blood Cancers
U.S. RESEARCH ROUNDUP-Autodesk, Hubspot, Oracle
Delaware jury finds Parse infringed three genetic-sequencing patents (updated)
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Brief: 10X Genomics Wins Patent Infringement Verdict Against Parse Biosciences